Live
- GAIL clocks net profit of Rs 2,672 crore in Q2
- Sr Men's National Hockey: Delhi, Karnataka, Bengal, A.P. win group matches on Day 2
- ‘Nation is proud of you’: West Bengal Guv to GRSE on laying keels of two NGOPVS
- Kirttane, Kapadia bag golden double as India wins 14 medals in Asia Pickleball Games
- Gurugram: 11 projects of GMDA worth Rs 249.77 crores approved
- Akali Dal stages statewide protests over ‘tardy’ paddy procurement in Punjab
- Firing on Nandan Kanan Express in Odisha, probe launched
- Indian Army Seizes Massive Cache Of Arms And Ammunition In Manipur Amid Ongoing Violence
- Polling Stations Open Across Eastern And Central US As Voters Head To The Ballots In Historic Election
- Hyatt set to expand brand presence in Nepal with hyatt regency lumbini
AstraZeneca drags Dr Reddy's to US court
Pharma major AstraZeneca has filed a petition in a USA court alleging Dr Reddy's Laboratories Limited is attempting to come out with generic version of its patented blockbuster drug Brilinta (Ticagrelor) in the US market before the expiration of a patent of the drug (276).
Hyderabad: Pharma major AstraZeneca has filed a petition in a USA court alleging Dr Reddy's Laboratories Limited is attempting to come out with generic version of its patented blockbuster drug Brilinta (Ticagrelor) in the US market before the expiration of a patent of the drug (276).
In a petition filed in the District Court of New Jersey on July 23, AstraZeneca alleged the Indian drug maker's proposed generic Brilinta will infringe the patent and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the US.
Brilinta is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
AstraZeneca requested the court to pass an order restraining Dr Reddy's from making, selling and also importing the drug into the United States.
Dr Reddy's submission of Abbreviated New Drug Application (ANDA) to obtain approval to engage in the commercial manufacture, use, offer to sell, or sale of generic Ticagrelor tablets prior to the expiration of the patent (276) constituted an act of infringement under US laws, AstraZeneca alleged.
Brilinta clocked $1.32 billion in sales in 2018 worldwide including $588 million in the USA, according to AstraZeneca.
Earlier through a letter, the Indian drug maker notified AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP that it had submitted its Ticagrelor ANDA to the USFDA.
AstraZeneca also said in its petition that DRL may manufacture, market, and/or sell within the United States the generic product described in the Ticagrelor ANDA if FDA approval is granted.
